Ka Yeung Mark Wong

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong et al. · Journal of Clinical Oncology · 2018 · 2.1K citations · Full text

Life Sciences, Immunology, Oncology +16

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

Thierry André, Sara Lonardi, Ka Yeung Mark Wong et al. · Annals of Oncology · 2022 · 253 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)

Heinz‐Josef Lenz, Eric Van Cutsem, María Luisa Limón et al. · Annals of Oncology · 2018 · 92 citations · Full text

Medicine, Immunology, Oncology +13

Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.

Michael J. Overman, Sara Lonardi, Francesco Leone et al. · Journal of Clinical Oncology · 2017 · 70 citations

Life Sciences, Immunology, Oncology +17

Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update.

Heinz‐Josef Lenz, Sara Lonardi, Vittorina Zagonel et al. · Journal of Clinical Oncology · 2020 · 60 citations

Medicine, Oncology, Pharmacotherapy +17